Pharma BD Deal Intelligence
Teva's $3.5B bet on Auspex Pharmaceuticals delivered—the deal secured a CNS drug portfolio and paid off with the outcome tracked well above the acquisition's initial critic reception, validating the pivot into central nervous system disease treatment even as the CNS space remained fiercely competitive.
Teva acquired Auspex Pharmaceuticals for $3.5B for CNS drug portfolio.
Teva acquired Auspex for $3.5 billion, gaining an innovative biopharmaceutical company specializing in deuterium chemistry to create novel therapies for…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Teva acquired Auspex Pharmaceuticals for $3.5B for CNS drug portfolio.
Huntington disease chorea is a small, defined symptomatic market (~30-40K US symptomatic HD patients) with two VMAT2 inhibitors competing on tolerability, and no approved disease-modifying therapy. VMAT2 inhibitors (approved for HD chorea): deutetrabenazine (Austedo and Austedo XR, Teva) — $1.23B global net revenue in 2023 per Teva IR across HD chorea and tardive dyskinesia, now the clear share leader due to improved neuropsychiatric tolerability and once-daily XR; tetrabenazine (Xenazine, Lundbeck/generic) is the original approved agent (2008) but largely displaced post-2017 by Austedo; valbenazine (Ingrezza, Neurocrine) received FDA approval for HD chorea August 2023 based on KINECT-HD, generating $1.84B global in 2023 (TD-dominant but HD expansion accelerating) per Neurocrine IR. Off-label antipsychotics (dopamine receptor antagonists): olanzapine (Zyprexa, Eli Lilly/generic), risperidone (Risperdal, J&J/generic), tiapride (not FDA-approved, EU use) are used symptomatically. Disease-modifying investigational (no approval): tominersen (Roche/Ionis, HTT ASO, Phase 2 GENERATION-HD2 after HD1 halt), AMT-130 (uniQure, AAV5 miHTT, Phase 1/2 positive interim 2024), PTC518 (PTC Therapeutics, HTT splicing modulator, Phase 2). Commercial lead takeaway: Austedo XR vs Ingrezza is the near-term share battle; a disease-modifying approval (AMT-130 earliest ~2027) would reshape the symptomatic ceiling.
Tardive dyskinesia (TD) is a ~500K US prevalent, ~$3B+ combined-franchise VMAT2 inhibitor duopoly with biosimilar-free patent runway through late decade. Selective VMAT2 inhibitors (approved for TD): valbenazine (Ingrezza, Neurocrine Biosciences) — $1.84B global net revenue 2023 per Neurocrine IR, the category leader following FDA approval April 2017; deutetrabenazine (Austedo and Austedo XR, Teva) — $1.23B global 2023 per Teva IR across TD and HD chorea combined, FDA-approved for TD August 2017; Austedo XR (once-daily extended release, launched 2023) closes the QD/BID gap vs Ingrezza. Non-selective VMAT2 inhibitor (older, non-TD-labeled but off-label use): tetrabenazine (Xenazine, Lundbeck/generic) — not FDA-approved for TD but used off-label pre-2017, now negligible. Discontinued class agents: reserpine (generic, largely abandoned due to depression risk). Investigational pipeline: no late-stage novel-MOA competitor; current development focuses on VMAT2 extended-release formulations and combination/adjunctive therapies. Ancillary off-label: clonazepam (Klonopin, generic), amantadine (Gocovri for LID, Adamas/Supernus) and botulinum toxin for focal TD. Commercial lead takeaway: Austedo XR vs Ingrezza is a pure commercial-execution battle — payer access, dosing convenience, and neuropsychiatric tolerability drive share. Both franchises retain MoS through late-2020s; entrants face a high clinical differentiation bar.
Teva completed $3.5B acquisition of Auspex Pharmaceuticals, gaining deutetrabenazine (later Austedo) for tardive dyskinesia and Huntington's chorea.
FDA approved Austedo for Huntington's chorea followed by tardive dyskinesia in August 2017, establishing a new franchise for Teva in movement disorders.
Austedo became blockbuster for Teva exceeding $1B annually, serving as critical growth driver offsetting generic drug revenue declines.
Austedo became Teva's most important branded drug at $1B+ annually. $3.5B acquisition delivered clear commercial value and strategic diversification beyond generics.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals (this deal) | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2005 | $7.4B | 62 |
| Teva Pharmaceutical Industries Ltd. / Barr Pharmaceuticals | 2008 | $7.5B | 58 |
← Browse all deals · How we score deals
More: 2015 deals · Teva Pharmaceutical Industries Ltd. deals · Neurology deals